Individual Behavior
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials
Senate Fails to Pass Bill Codifying Access to Contraception Amid Republican Opposition
Contraception, Senate Vote, Republican Opposition, Reproductive Rights, Birth Control
Legislators Profit from Bill Restricting Chinese Biotech Firms
Congress, stock trading, China biotech ban, financial gain, legislative influence, conflict of interest.
FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer
FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.
Novel Monthly Hemophilia A Treatment by Novos Poses Challenge to Roche’s Hemlibra
Hemophilia A, Novos, Roche, Hemlibra, monthly treatment, performance, challenge.
AbbVie Emerges as Leading Immunology Company in Doctor Rankings, Surpassing Pfizer and Johnson & Johnson
AbbVie, Pfizer, Johnson & Johnson, doctor ranking, immunology companies, pharmaceutical industry, market performance, reputation, product portfolio.